What are the normal therapeutic trough concentrations for tacrolimus (immediate-release and extended-release) in kidney and liver transplant patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Tacrolimus Normal Trough Levels

For liver transplant recipients, target tacrolimus trough levels of 6-10 ng/mL during the first month, followed by 4-8 ng/mL thereafter, with lower ranges (4-7 ng/mL first month, then 3-5 ng/mL) when combined with other immunosuppressants to preserve renal function. 1

Liver Transplantation

The 2024 EASL guidelines provide the most current, authoritative recommendations for tacrolimus monitoring after liver transplantation:

Monotherapy Targets

  • First month: 6-10 ng/mL
  • After first month: 4-8 ng/mL
  • Beyond first year: 4-6 ng/mL 1

Combination Therapy (Renal-Sparing Regimens)

When tacrolimus is combined with basiliximab induction and/or additional immunosuppressants (MMF, azathioprine, or mTOR inhibitors):

  • First month: 4-7 ng/mL
  • After first month: 3-5 ng/mL 1

These lower targets are strongly recommended for patients at risk of post-transplant renal dysfunction (pre-existing kidney dysfunction, advanced liver failure, hyponatremia, or high BMI). 1

Important Caveats for Liver Transplant

  • The original regulatory target of 10-15 ng/mL is now considered too high and associated with unnecessary nephrotoxicity 1
  • Many long-term survivors maintain normal liver function with levels substantially lower than these thresholds, though the safety of aggressive minimization requires monitoring for subclinical rejection via donor-specific antibodies and transient elastography 1
  • Patients in poor clinical condition or requiring prolonged ICU stay typically need lower doses than standard recommendations 1

Kidney Transplantation

The 2010 KDIGO guidelines recommend monitoring tacrolimus using 12-hour trough concentrations (C0) 2, though specific target ranges are not explicitly stated in these guidelines. However, recent high-quality research provides important guidance:

Evidence-Based Targets for Kidney Transplant

A 2024 multicenter study of 11,868 kidney transplant recipients found optimal ranges that balanced graft survival with safety:

  • 2-12 months post-transplant: 5.0-7.9 ng/mL (with 5.0-5.9 ng/mL showing the best outcomes)
  • 12-72 months post-transplant: 5.0-6.9 ng/mL 3

These ranges were associated with:

  • Reduced composite allograft outcomes (adjusted HR 0.68-0.81)
  • Lower rates of severe infection, malignancy, and mortality
  • Better preservation of renal function 3

Historical Context

  • FDA labeling indicates most patients are stable with trough levels between 5-20 ng/mL, with long-term patients often maintained at the low end 4
  • Older data suggested 5-10 ng/mL as a therapeutic range 5
  • Levels above 20 ng/mL are associated with increased nephrotoxicity, neurotoxicity, and infections 6

Heart Transplantation

According to FDA labeling, target ranges for heart transplant recipients are:

  • 1 week to 3 months: 8-20 ng/mL (approximately 80% of patients)
  • 3-18 months: 6-18 ng/mL (approximately 80% of patients) 4

The pre-defined target range in clinical trials was 5-15 ng/mL 4.

Monitoring Frequency

The KDIGO guidelines recommend measuring tacrolimus levels 2:

  • Every other day during immediate post-operative period until target reached
  • Whenever medication changes occur that may affect blood levels
  • Whenever renal function declines (possible nephrotoxicity or rejection)

Extended-Release vs Immediate-Release Formulations

Both formulations achieve similar systemic exposure and trough concentrations when dosed appropriately. Extended-release tacrolimus (once-daily) and immediate-release (twice-daily) show comparable pharmacokinetics, with target trough ranges remaining the same 7. The key difference is the delayed-release profile of extended-release formulations, but therapeutic drug monitoring targets do not change between formulations.

Critical Clinical Pearls

  • Tacrolimus levels correlate poorly with peak concentrations in some patients: Those with low C0/dose ratios may have unexpectedly high peaks causing toxicity, while those needing very low doses may be underexposed despite adequate troughs 8
  • Anemia affects interpretation: Hematocrit-adjusted tacrolimus levels may better predict AKI risk, as tacrolimus is highly erythrocyte-bound 9
  • Cumulative exposure matters: Three-month cumulative AUC is a key determinant of nephrotoxicity, suggesting early aggressive monitoring is crucial 10
  • Food significantly affects absorption: Tacrolimus should be taken consistently with or without food, as meals can decrease AUC by 27-39% and Cmax by 50-77% 4

References

5
Research

Tacrolimus levels in adult patients with renal transplant.

Proceedings of the Western Pharmacology Society, 2009

Related Questions

When should tacrolimus (immunosuppressive medication) levels be checked in a patient after starting the medication following an organ transplant?
In a liver transplant recipient with an active infection and an elevated tacrolimus trough level, how should the tacrolimus dosing be adjusted and what monitoring is recommended?
For a female liver transplant recipient more than five years post‑transplant who is taking tacrolimus 1 mg twice daily and has a trough level of 4.4 ng/mL, is this level acceptable and what adjustments, if any, are recommended?
What are the appropriate trough tacrolimus (TAC) levels for transplant patients?
What are the recommended dosing, target trough levels, monitoring, and adverse‑effect management for calcineurin inhibitors (cyclosporine and tacrolimus) in adult renal, liver, or heart transplant patients and for severe eczema?
How should I evaluate and manage a patient presenting with pancytopenia and complete hair loss?
In adults aged 40–50 years with a BMI > 27 kg/m², which drug provides greater weight loss: semaglutide or Mounjaro (tirzepatide)?
When should selective serotonin reuptake inhibitors (SSRIs) be started in post‑stroke patients, and what are the recommended dosing, contraindications, monitoring, and duration of therapy?
How should I switch from Cannify Pure cannabis flower with an 18% THC and 1% CBD profile to an appropriate cannabinoid extract, and what dosing regimen should I use?
How should a double‑strength norepinephrine infusion be initially started?
What amount of cannabis extract corresponds to 0.3 g of flower and a total daily dose of 1.5 g, and can you suggest an example Tilray product?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.